Seth N Redmond, PhD

Genomic epidemiology, disease surveillance, and decision-grade real-world evidence

Public-health and biomedical decisions increasingly depend on converting genomic data into actionable evidence. I develop and implement genomic methods that bridge research and real-world use, spanning culture-free TB sequencing and resistance prediction, respiratory pathogen surveillance, and vector and malaria population genomics.

My work focuses on turning pathogen and vector genomics into decision-grade inputs for surveillance, intervention planning, and disease control—across both pharma / real-world evidence and global health implementation contexts.

Applied across:


What I Build

My work centres on operational systems, not isolated analyses:


Where This Fits in Decision-Making

Across projects, genomics is used to support decisions such as:


Portfolio: Selected Works:


Contact

I’m interested in roles and collaborations spanning pharma / biotech, real-world evidence, and global health, particularly where genomics informs real-world decisions.

seth.redmond@yale.edu / seth.redmond@gmail.com



Culture-free TB whole-genome sequencing and drug resistance profiling

Context
Tuberculosis sequencing remains slow and laborious. Reliable sequencing typically requires intermediate culturing, which introduces significant delay and is poorly suited to in high-burden settings, limiting the use of genomics for timely treatment decisions.

What I built
A tiled amplicon sequencing approach for Mycobacterium tuberculosis that enables whole-genome sequencing directly from patient sputum, without an intermediate culture step, enabling rapid comprehensive resistance profiling.

Why it matters

Kalinich et al, JCM 2025 Fig 1

Links


RSV genomic surveillance in a hospital-linked system

Context
With the rollout of RSV monoclonal antibodies and vaccines, the limiting factor is no longer the availability of interventions, but the ability to target them effectively. Local transmission dynamics and age-structured spread are poorly resolved by routine surveillance.

What I built
An end-to-end RSV genomic surveillance system integrated with a major hospital network, linking viral sequencing with epidemiological metadata from routine clinical sampling.

Why it matters

Links


Global migration and insecticide resistance in Aedes aegypti

Context
Vector control strategies often assume geographically stable and genetically homogeneous mosquito populations, despite differences in insecticide resistance, host preference, and vector capacity. Aedes is known to exhibit two subspecies, with the ancestral African form thought to have a lower capacity to transmit arboviruses than the derived global form.

What I built
Population admixture analyses between African and global populations of Aedes aegypti to resolve contemporary migration patterns, track the global spread of pyrethroid resistance alleles, and identify regions of reinvasion that could affect dengue transmission.

Why it matters

Crawford et al, Science 2025 Fig 4

Links


Malaria transmission network inference

Context
Almost all genomic epidemiology methods for P. falciparum rely on pairwise relatedness, however as malaria transmission declines, these methods become less applicable, just at the point where elimination efforts depend on identifying who is infecting whom.

What I built
Genomic epidemiology methods combining wet-lab and computational approaches to increase variant calling fidelity and using genetic distance from de novo mutations to infer individual-level transmission networks for Plasmodium falciparum.

Why it matters

Redmond et al, MBE 2018 Fig 4

Links
github / Redmond et al, Mol Bio Evo 2018


What I Build

My work centres on operational systems, not isolated analyses:


Where This Fits in Decision-Making

Across projects, genomics is used to support decisions such as: